A Phase 1/2 interventional study of Blinatumomab in Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia, sponsored by Amgen. Active, not recruiting at 5 sites in 2 countries. Open to participants aged 28 Days and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Amgen · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing blinatumomab in Neoplasm, Residual — 3 open to participants now, 6 under way, none of them phase 3. blinatumomab · Neoplasm, Residual.
Among the 17 studies testing blinatumomab in Neoplasm, Residual, this one is the 6th largest by planned enrollment, is one of 3 that started in 2025, is one of 3 in phase 1/2, and was the 17th registered.
293 studies on the registry are indexed under Neoplasm, Residual; 137 are open to participants now.
Browse Neoplasm, Residual studies →3 of the 17 studies testing blinatumomab in Neoplasm, Residual are open now, in 1 country. Recruiting first, the newest first:
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–65
Zhejiang University · Sites in China
Ages 18–70
The Children's Hospital of Zhejiang University School of Medicine
Ages 1–18
By country, each count listing its studies:
blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 94 Neoplasm, Residual studies recruiting now, 59 (63%) set no upper age limit and 24 (26%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.
This study: 28 Days and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 4 1
First in 2008; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 104 is above the median of 50 across 198 interventional studies indexed under Neoplasm, Residual.
Median enrollment 31 across the 17 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 17 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 5 studies filed under Neoplasm, Residual — fewer than ten, so there is no comparison to draw.
2 of the studies testing blinatumomab in Neoplasm, Residual that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003737First Affiliated Hospital of Zhejiang UniversityBlinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation | 2027-02-05 |
| NCT04521231AmgenA Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL | 2027-11-24 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing blinatumomab in Neoplasm, Residual, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
293 studies on the registry are indexed under Neoplasm, Residual; 137 are open to participants now.
This study's planned enrollment of 104 is above the median of 50 across 198 interventional studies indexed under Neoplasm, Residual.
Browse Neoplasm, Residual studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Neoplasm, Residual, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Phase 1b and Phase 2 cohort in participants with R/R B-ALL:
For Phase 2 cohort in participants with MRD+ B-ALL:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with R/R B-ALL will receive blinatumomab as SC injection to determine the pediatric recommended Phase 2 dose (RP2D).
Drug: Blinatumomab
Participants with R/R B-ALL will receive blinatumomab as SC injection at RP2D.
Drug: Blinatumomab
Participants with MRD+ B-ALL will receive blinatumomab as SC injection at RP2D.
Drug: Blinatumomab
Blinatumomab will be administered as a SC injection for up to 5 cycles (each cycle will be 35 days).
Phase 1b: Number of Participants who Experienced Dose Limiting Toxicities (DLTs)
Time frame: Up to 29 days
Phase 1b: Number of Participants who Experienced Treatment-emergent Adverse Events (TEAEs)
Time frame: Up to approximately 7 months
Phase 1b: Number of Participants who Experienced Serious TEAEs
Time frame: Up to 2 years and 7 months
Phase 1b: Number of Participants who Experienced Treatment-related TEAEs
Time frame: Up to approximately 7 months
Phase 1b: Number of Participants who Experienced AEs of Interest (EOI)
Time frame: Up to approximately 7 months
Phase 2; R Cohort: Number of Participants who had Complete Remission/Complete Remission with Partial Hematological Recovery (CR/CRh) Within the First 2 Cycles
Time frame: Up to 70 days
Phase 2; M Cohort: Number of Participants who had CR with MRD Negative Response Within the First 2 Cycles
MRD negative response = MRD level \< 10\^-4 (0.01%).
Time frame: Up to 70 days
Phase 1b: Number of Participants who had CR/CRh Within the First 2 Cycles
Time frame: Up to 70 days
Phase 1b: Number of Participants who had CR Within the First 2 Cycles
Time frame: Up to 70 days
Phase 1b: Number of Participants who had CR/CRh/Complete Remission with Incomplete Hematological Recovery (CRi) or Blast Free Hypoplastic or Aplastic Bone Marrow (BM) Within the First 2 Cycles
Time frame: Up to 70 days
Phase 1b: Number of Participants with a MRD Negative Response Within the First 2 Cycles
MRD negative response = MRD level \< 10\^-4 (0.01%).
Time frame: Up to 70 days
Phase 1b: Duration of Response (DOR)
DOR is defined as the time from the first response of CR/CRh within the first 2 cycles until hematological relapse (Including extramedullary \[EM\] relapse) per investigator's assessment or death due to any cause, whichever occurs first.
Time frame: Up to 2 years and 7 months
Phase 1b: Maximum Concentration (Cmax) of Blinatumomab
Time frame: Up to approximately 7 months
Phase 1b: Time to Maximum Concentration (Tmax)
Time frame: Up to approximately 7 months
Phase 1b: Area Under the Concentration Time Curve (AUC)
Time frame: Up to approximately 7 months
Phase 1b: Number of Participants with Anti-blinatumomab Antibodies
Time frame: Cycle 1, Day 1 and Cycle 2, Day 1 (Cycle Duration = 35 days)
Phase 2: Number of Participants who had CR/CRh with MRD Negative Response Within the First 2 Cycles
MRD negative response = MRD level \< 10\^-4 (0.01%).
Time frame: Up to 70 days
Phase 2: DOR
DOR is defined as the time from the first response of CR/CRh within the first 2 cycles until hematological relapse (Including EM relapse) per investigator's assessment or death due to any cause, whichever occurs first.
Time frame: Up to 2 years and 7 months
Phase 2; R Cohort: Number of participants who had CR Within the First 2 Cycles
Time frame: Up to 70 days
Phase 2; R Cohort: Number of participants who had CR/CRh/CRi and Blast Free Hypoplastic or Aplastic BM Within the First 2 Cycles
Time frame: Up to 70 days
Phase 2: Overall Survival (OS)
OS is defined as the time from the first dose until death due to any cause.
Time frame: Up to 2 years and 7 months
Phase 2: Number of Participants who Experienced TEAEs, Serious TEAEs, Treatment Related TEAEs and EOIs
Time frame: Up to 2 years and 7 months
Phase 2: Blinatumomab Serum Concentrations
Time frame: Up to 175 days
Phase 2: Number of Participants with Anti-blinatumomab Antibodies
Time frame: Cycle 1, Day 1 and Cycle 2, Day 1 (Cycle Duration = 35 days)
Phase 2; M Cohort: Number of participants who had CR/CRh/CRi and Blast Free Hypoplastic or Aplastic BM with MRD Negative Response Within the First 2 Cycles
MRD negative response = MRD level \< 10\^-4 (0.01%).
Time frame: Up to 70 days
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Started Dec 2025 (actual). Primary completion is estimated for Mar 2031, 62 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Dec 2028 → Mar 2031 and completion Jun 2030 → Sep 2032.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Blinatumomab